Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
06
08
2021
accepted:
16
03
2022
revised:
15
03
2022
pubmed:
4
5
2022
medline:
1
9
2022
entrez:
3
5
2022
Statut:
ppublish
Résumé
EZH2 coding mutation (EZH2
Identifiants
pubmed: 35504958
doi: 10.1038/s41379-022-01074-y
pii: S0893-3952(22)00276-9
doi:
Substances chimiques
Transcription Factors
0
EZH2 protein, human
EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein
EC 2.1.1.43
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1212-1219Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.
Références
Swerdlow, S. H., Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition. (IARC, 2017).
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F. et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120, 2454–2465 (2012).
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G. et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364, 2496–2506 (2011).
Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616–3627; quiz 3699 (2013).
Sperling, A. S., Gibson, C. J. & Ebert, B. L. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer 17, 5–19 (2017).
Haferlach, T., Nagata, Y., Grossmann, V., Okuno, Y., Bacher, U., Nagae, G. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241–247 (2014).
Bejar, R., Levine, R. & Ebert, B. L. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 29, 504–515 (2011).
Bejar, R., Stevenson, K. E., Caughey, B. A., Abdel-Wahab, O., Steensma, D. P., Galili, N. et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 30, 3376–3382 (2012).
Hosono, N. Genetic abnormalities and pathophysiology of MDS. Int J Clin Oncol 24, 885–892 (2019).
Malcovati, L., Papaemmanuil, E., Bowen, D. T., Boultwood, J., Della Porta, M. G., Pascutto, C. et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 118, 6239–6246 (2011).
Garcia-Manero, G., Shan, J., Faderl, S., Cortes, J., Ravandi, F., Borthakur, G. et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22, 538-543 (2008).
Xu, F. & Li, X. The role of histone methyltransferase EZH2 in myelodysplastic syndromes. Expert Rev Hematol 5, 177–185 (2012).
Nikoloski, G., Langemeijer, S. M., Kuiper, R. P., Knops, R., Massop, M., Tonnissen, E. R. et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42, 665–667 (2010).
Wu, L., Song, L., Xu, L., Chang, C., Xu, F., Wu, D. et al. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes. Tumour Biol 37, 4633–4640 (2016).
Sashida, G., Harada, H., Matsui, H., Oshima, M., Yui, M., Harada, Y. et al. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation. Nat Commun 5, 4177 (2014).
Gollner, S., Oellerich, T., Agrawal-Singh, S., Schenk, T., Klein, H. U., Rohde, C. et al. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nature Medicine 23, 69–78 (2017).
Lambert, M., Alioui, M., Jambon, S., Depauw, S., Van Seuningen, I. & David-Cordonnier, M. H. Direct and indirect targeting of HOXA9 transcription factor in acute myeloid leukemia. Cancers (Basel) 11, 837 (2019).
Li, Y., Zhang, M., Sheng, M., Zhang, P., Chen, Z., Xing, W. et al. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia. J Cancer Res Clin Oncol 144, 1065–1077 (2018).
Rinke, J., Chase, A., Cross, N. C. P., Hochhaus, A. & Ernst, T. EZH2 in Myeloid Malignancies. Cells 9, 1639 (2020).
Kanagal‐Shamanna, R., Bueso‐Ramos, C. E., Barkoh, B., Lu, G., Wang, S., Garcia‐Manero, G. et al. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild‐type TP53. Cancer 118, 2879–2888 (2012).
ISCN 2016 - An International System for Human Cytogenomic Nomenclature (2016). In: Simons A. McGowan-Jordan J., Schmid M. (ed). (2016).
Kanagal-Shamanna, R., Luthra, R., Yin, C. C., Patel, K. P., Takahashi, K., Lu, X. et al. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget 7, 14251–14258 (2016).
Montalban-Bravo, G., Kanagal-Shamanna, R., Sasaki, K., Patel, K., Ganan-Gomez, I., Jabbour, E. et al. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv 3, 922–933 (2019).
Kanagal-Shamanna, R., Singh, R. R., Routbort, M. J., Patel, K. P., Medeiros, L. J. & Luthra, R. Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory. Expert Review of Molecular Diagnostics 16, 461–472 (2016).
Wu, H., Zeng, H., Dong, A., Li, F., He, H., Senisterra, G. et al. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations. PLoS One 8, e83737 (2013).
Yap, D. B., Chu, J., Berg, T., Schapira, M., Cheng, S. W., Moradian, A. et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117, 2451–2459 (2011).
Morin, R. D., Johnson, N. A., Severson, T. M., Mungall, A. J., An, J., Goya, R. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42, 181–185 (2010).
Berg, T., Thoene, S., Yap, D., Wee, T., Schoeler, N., Rosten, P. et al. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Blood 123, 3914–3924 (2014).
Cabrero, M., Wei, Y., Yang, H., Ganan-Gomez, I., Bohannan, Z., Colla, S. et al. Down-regulation of EZH2 expression in myelodysplastic syndromes. Leuk Res 44, 1–7 (2016).
Shirahata-Adachi, M., Iriyama, C., Tomita, A., Suzuki, Y., Shimada, K. & Kiyoi, H. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome. Leuk Res 63, 90–97 (2017).
Wang, Y., Hou, N., Cheng, X., Zhang, J., Tan, X., Zhang, C. et al. Ezh2 acts as a tumor suppressor in Kras-driven lung adenocarcinoma. Int J Biol Sci 13, 652–659 (2017).
Walter, M. J., Shen, D., Ding, L., Shao, J., Koboldt, D. C., Chen, K. et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 366, 1090–1098 (2012).
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 30, 413–421 (2012).
Kulasekararaj, A. G., Smith, A. E., Mian, S. A., Mohamedali, A. M., Krishnamurthy, P., Lea, N. C. et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 160, 660–672 (2013).
Hasegawa, N., Oshima, M., Sashida, G., Matsui, H., Koide, S., Saraya, A. et al. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome. Leukemia 31, 861–871 (2017).
Muto, T., Sashida, G., Oshima, M., Wendt, G. R., Mochizuki-Kashio, M., Nagata, Y. et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 210, 2627–2639 (2013).
Wang, J., Ai, X., Gale, R. P., Xu, Z., Qin, T., Fang, L. et al. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes. Leuk Res 37, 305–311 (2013).
Abdel-Wahab, O., Adli, M., LaFave, L. M., Gao, J., Hricik, T., Shih, A. H. et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22, 180–193 (2012).
Boultwood, J., Perry, J., Pellagatti, A., Fernandez-Mercado, M., Fernandez-Santamaria, C., Calasanz, M. J. et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 24, 1062–1065 (2010).
Gelsi-Boyer, V., Trouplin, V., Adelaide, J., Bonansea, J., Cervera, N., Carbuccia, N. et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 145, 788–800 (2009).
Hosono, N., Makishima, H., Jerez, A., Yoshida, K., Przychodzen, B., McMahon, S. et al. Recurrent genetic defects on chromosome 7q in myeloid neoplasms. Leukemia 28, 1348–1351 (2014).
Jerez, A., Sugimoto, Y., Makishima, H., Verma, A., Jankowska, A. M., Przychodzen, B. et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood 119, 6109–6117 (2012).
Dubois, S., Mareschal, S., Picquenot, J. M., Viailly, P. J., Bohers, E., Cornic, M. et al. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget 6, 16712–16724 (2015).
Mcgraw, K. L., Nguyen, J., Alali, N., Song, J. M., Sallman, D., Padron, E. et al. EZH2 protein expression is decreased in MDS and MDS/MPN and correlated with EZH2 mutation status, chromosomal 7 abnormalities and clinical outcome. Blood 128 (2016).
Veitia, R. A., Bottani, S. & Birchler, J. A. Gene dosage effects: nonlinearities, genetic interactions, and dosage compensation. Trends Genet 29, 385–393 (2013).
Kim, E., Ilagan, J. O., Liang, Y., Daubner, G. M., Lee, S. C., Ramakrishnan, A. et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27, 617–630 (2015).
Gall Troselj, K., Novak Kujundzic, R. & Ugarkovic, D. Polycomb repressive complex’s evolutionary conserved function: the role of EZH2 status and cellular background. Clin Epigenetics 8, 55 (2016).
Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343–349 (2011).
Zhou, Z., Gao, J., Popovic, R., Wolniak, K., Parimi, V., Winter, J. N. et al. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. Leuk Lymphoma 56, 2895–2901 (2015).
Chase, A., Score, J., Lin, F., Bryant, C., Waghorn, K., Yapp, S. et al. Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia 34, 3206–3214 (2020).